Open AccessSignificance of Chromogranin A in Diagnosis and Prognosis of Neuroendocrine Tumors
Author(s) -
Н. В. Любимова,
Ю. С. Тимофеев,
Т. К. Чурикова,
А. Е. Кузьминов,
Н. Е. Кушлинский
Publication year - 2019
Publication title -
medicinskij alfavit
Language(s) - English
Resource type - Journals
eISSN - 2949-2807
pISSN - 2078-5631
DOI - 10.33667/2078-5631-2019-2-17(392)-19-22
Subject(s) - chromogranin a , neuroendocrine tumors , biomarker , medicine , immunoassay , basal (medicine) , clinical significance , gastroenterology , diagnostic biomarker , diagnostic accuracy , endocrinology , oncology , immunohistochemistry , biology , immunology , biochemistry , antibody , insulin
We present the comparative study of plasma chromogranin A (CgA) levels measured in 232 patients with different types of neuroendocrine tumors (NETs) and 66 healthy individuals using enzyme immunoassay Chromogranin A ELISA kit (Dako). CgA levels were significantly higher in patients with all types of NETs than in healthy subjects. CgA secretion were highly variable. The study demonstrate high diagnostic sensitivity of CgA, which was 80.6 % in overall group of NETs with specificity 98.5 %. We confirmed the prognostic significance of CgA, in this case the high basal levels of CgA (above 100 U/l) were significantly associated with less favorable prognosis of progression free survival after different types of treatment. The data confirms high efficiency of CgA as biomarker, which measurement enhances the accuracy of diagnosis and prognosis of NETs.